🎯 Schemes & WelfareMAINS · GS2.13

India launches world's largest free HPV vaccination drive

A nationwide single-dose campaign vaccinates 12 million 14-year-old girls against the virus that causes cervical cancer — the largest free HPV programme on record.

What happened

Speaking virtually at a press briefing held at WHO Headquarters in Geneva, Union Health Minister J. P. Nadda set out India's full strategy to eliminate cervical cancer, built on four arms: prevention, screening, early detection and timely treatment.
The centrepiece is a nationwide HPV (human papillomavirus) vaccination campaign inaugurated on 28 February 2026 by the Prime Minister, targeting roughly 12 million adolescent girls aged 14, to be completed over a 90-day rollout.
It uses a single dose of the quadrivalent Gardasil vaccine, offered free at government health facilities, voluntary and given only with parental consent, under the vision "Swasth Nari, Sashakt Parivar" (a healthy woman, an empowered family).
WHO Director-General Dr Tedros Adhanom Ghebreyesus described it as the world's largest free HPV vaccination drive, at roughly 12 million girls a year.
The briefing also reaffirmed India's endorsement of the WHO's global 90-70-90 cervical-cancer elimination targets for 2030, with South Africa's Health Minister Dr Aaron Motsoaledi also present.

Background & context

Cervical cancer is the only major cancer that is almost entirely preventable, because nearly all cases are caused by persistent infection with a few high-risk types of the human papillomavirus, a sexually transmitted virus. That biological fact is what makes a vaccine-plus-screening strategy possible: stop the infection in adolescent girls before exposure, then catch any pre-cancerous changes early in adult women through routine screening. India carries a heavy share of the global burden — the release records more than 80,000 deaths and about 42,000 new cases every year, making cervical cancer one of the leading causes of cancer death among Indian women.

India's response sits inside an existing public-health architecture rather than being a standalone project. Population-based screening already runs under the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), the central programme that addresses the four big lifestyle-linked disease groups — cardiovascular disease, diabetes, stroke and common cancers. Under NP-NCD, women aged 30–65 are screened for cervical cancer using Visual Inspection with Acetic Acid (VIA), a low-cost test in which a clinician applies dilute acetic acid (vinegar) to the cervix and looks for the whitening that flags pre-cancerous tissue. This screening is delivered at Ayushman Arogya Mandirs — the rebranded name for the Health and Wellness Centres that form the primary-care foundation of Ayushman Bharat. The release states that over 86 million women have already been screened, the demand-side base onto which the new vaccination campaign now adds a supply-side, primary-prevention layer.

The vaccination campaign is also notable for its scientific design. India has adopted a single-dose schedule rather than the older two- or three-dose regimens, following the recommendation of the WHO's Strategic Advisory Group of Experts and India's own National Technical Advisory Group on Immunization (NTAGI) — the expert body that advises the government on which vaccines to introduce and on what schedule. A single dose lowers cost, simplifies logistics and improves completion rates, which is decisive when the target is 12 million girls in 90 days. The campaign rides on two digital systems India built during the COVID-19 effort: U-WIN, the digital immunization registry that records each beneficiary and dose (an extension of the Co-WIN/eVIN lineage to routine immunization), and eVIN (Electronic Vaccine Intelligence Network), which tracks vaccine stocks and cold-chain temperatures in real time so that doses remain potent from the state store down to the session site.

A word on the vaccine itself helps place the campaign. Gardasil is a quadrivalent HPV vaccine, meaning it protects against four virus types — two high-risk types responsible for the large majority of cervical cancers and two low-risk types linked to genital warts. India is not solely import-dependent here: an indigenous HPV vaccine has been developed domestically, which over time can lower the per-dose cost and secure supply for a programme of this size. The vaccine works prophylactically — it primes the immune system before exposure to the virus, which is precisely why the target group is 14-year-olds, an age chosen to vaccinate girls ahead of likely exposure while remaining within a single, school-and-community-reachable cohort. It is this "vaccinate-before-exposure" logic, not any treatment effect, that drives the age choice and the whole-cohort approach.

It is worth situating the effort against a peer. Several countries have run national HPV programmes for over a decade, and the strongest evidence comes from places where high adolescent coverage was reached early and sustained, producing sharp falls in pre-cancerous lesions and, more recently, in invasive cervical cancer among the first vaccinated cohorts. India's distinguishing feature is sheer scale — at roughly 12 million girls a year, no single national programme has attempted free HPV vaccination at this volume, which is exactly what the WHO Director-General highlighted. The comparison also sets the bar: the long-run payoff appears only when coverage is both high and maintained year after year, so the test for India is not the first 90-day campaign but whether successive cohorts are reached with equal completeness.

For Prelims

The campaign: nationwide HPV vaccination drive launched 28 February 2026 by the Prime Minister; targets ~12 million adolescent girls aged 14; completed over a 90-day window; vision tagline "Swasth Nari, Sashakt Parivar."
The vaccine: single dose of the quadrivalent Gardasil (HPV); schedule endorsed by WHO and NTAGI; free at government facilities; voluntary with parental consent.
Digital backbone: beneficiaries tracked on U-WIN; vaccine stock and cold-chain managed via eVIN.
Screening arm: VIA (Visual Inspection with Acetic Acid) screening for women aged 30–65 at Ayushman Arogya Mandirs, under NP-NCD; over 86 million women screened.
Disease burden: India records >80,000 cervical-cancer deaths and ~42,000 new cases annually.
The global target set — WHO 90-70-90 (by 2030): 90% of girls fully vaccinated against HPV by age 15 · 70% of women screened with a high-performance test by ages 35 and 45 · 90% of women with cervical disease receiving treatment.
WHO recognition: Director-General Dr Tedros Adhanom Ghebreyesus called it the world's largest free HPV vaccination drive.
What it is NOT: it is not part of the routine Universal Immunization Programme schedule for infants — it is a targeted adolescent-girl campaign; it is not mandatory (consent-based and voluntary); the vaccine treats no existing cancer — it prevents the HPV infection that causes it, which is why it is given before likely exposure. HPV vaccination does not replace screening — the two are complementary arms of the same strategy. The "Arogya Mandir" delivering screening is the renamed Health and Wellness Centre, not a new institution.
How the four pillars line up: (1) prevention = HPV vaccination of 14-year-old girls; (2) screening = VIA at Ayushman Arogya Mandirs under NP-NCD; (3) early detection = follow-up of screen-positive women; (4) treatment = onward care. Memorising the four-pillar set survives a "how many of the following are part of India's cervical-cancer strategy" question.

For UPSC: India's HPV drive (launched 28 Feb 2026) gives ~12 million girls aged 14 a single Gardasil dose, tracked on U-WIN; it pairs with VIA screening under NP-NCD at Ayushman Arogya Mandirs and feeds the WHO 90-70-90 cervical-cancer elimination targets for 2030 — the world's largest free HPV campaign.

Why it matters

The significance is best read as a problem-and-solution pair. The problem is that cervical cancer kills more than 80,000 Indian women a year despite being preventable; most cases are detected late, when treatment is harder and costlier, and the burden falls disproportionately on women in lower-income and rural households who have least access to screening. The solution India is testing at scale is to attack the disease before it begins — vaccinating an entire age-cohort of adolescent girls — while simultaneously widening screening for adult women already past the vaccination window. The choice of a single-dose schedule, free delivery and consent-based rollout is what turns an ambitious target into an operationally feasible one. The campaign also demonstrates a wider point about Indian public health: the digital immunization and cold-chain platforms (U-WIN, eVIN) and the primary-care network (Ayushman Arogya Mandirs) built for COVID-19 and for non-communicable diseases are now being reused to deliver a cancer-prevention programme — infrastructure compounding across programmes. Finally, the WHO Director-General's recognition places India's domestic effort inside a global commitment, the 90-70-90 elimination strategy, giving the campaign a yardstick against which progress to 2030 can be measured.

For Mains

Anchor

A question on government health interventions or on the delivery of welfare to women can be built directly around this campaign — "Examine how India is operationalising the WHO cervical-cancer elimination strategy" — using the four-pillar prevention-to-treatment design as the spine of the answer.

Substantiation

The hard numbers — 12 million girls aged 14, a 90-day single-dose rollout, >80,000 deaths and ~42,000 new cases a year, over 86 million women already screened — supply concrete data to ground an argument about scale, burden and reach.

Exemplification

Offers a textbook example of preventive, primary-care-led public health that reuses existing digital infrastructure (U-WIN, eVIN) and the Ayushman Arogya Mandir network — useful in answers on health-system strengthening or on technology in governance.

Problematisation

The release itself implies the gap: with >80,000 deaths annually and screening so far reaching a fraction of eligible women, sustaining single-dose coverage, parental uptake and screening follow-through across States is the unresolved challenge a critical answer should foreground.

Way-forward

Points toward closing the cycle — pairing high adolescent vaccination coverage with universal screening of the 30–65 cohort and assured treatment for screen-positive women — as the path to the 90-70-90 milestone by 2030.

Position

States the government's stance: cervical cancer is treated as an eliminable disease, and India has publicly committed to the WHO 90-70-90 targets for 2030.

Deploys into: welfare schemes for women and vulnerable sections (GS2.12); health and human-resource development, and government policies and interventions in the health sector (GS2.13/2.10); India and global health institutions (the WHO link).

Ministry of Health and Family Welfare · 2026-03-05 · PRID 2235710 · PIB source ↗

Related: HPV & cervical-cancer elimination hub · Schemes & Welfare · This week's cards